Featured products include the Cytation 5 cell imaging multimode readerfrom BioTek, an ebola disinfectant from Mueller Sports Medicine, and a lab coat with multiple pockets for electronic devices from ScotteVest.
The settlement between Illumina and Sequenom creates a pool for joint use of the companies’ intellectual properties in noninvasive prenatal testing.
Abbott says its latest platform has the potential to change how serious infections are detected and identified, providing doctors with information needed to start treating critically ill patients sooner, and reducing inappropriate use of broad-spectrum antibiotics.
The ATUMtome, an automated tape-collecting ultramicrotome from RMC Products and Zeiss, uses an innovative tape collecting method that facilitates the efficient sectioning and handling of large volumes of biological samples for 3-D image reconstruction.
Bio-Rad Laboratories has received FDA premarket approval for its Geenius HIV-1/HIV-2 supplemental assay, which can differentiate circulating antibodies to human immunodeficiency virus types 1 and 2 in whole blood, serum, and plasma. Requiring little training, the test produces results within 30 minutes.
With its acquisition of Ariosa Diagnostics, Roche enters the market for noninvasive prenatal testing and cell-free DNA testing services.
An international collaboration expects the handheld, battery-powered Freedom4 platform will enable rapid field deployment of a gold-standard molecular test.
Clinical study presented at the Society of Urologic Oncology annual meeting validates active surveillance threshold using Prolaris score.
In a collaboration with PerkinElmer and investigators at UCLA, OncoSec Medical is developing biomarker tests to evaluate a patient’s immune response to cancer.
Australian researchers have formed an international team to help quickly determine life-threatening cases of prostate cancer compared with cancer that may not require treatment.